Does Humana Cover Sildenafil (Generic)?

Humana Commercial Plan Coverage for Generic Sildenafil

Humana's employer-sponsored and individual commercial plans generally list generic sildenafil citrate on their preferred generic tier, which is Tier 1 on the standard four- or five-tier formulary. This means most members pay between $0 and $15 per fill, depending on the specific plan design and pharmacy network.

The FDA approved sildenafil citrate in 1998 for erectile dysfunction after the landmark trial by Goldstein et al. (N=532) demonstrated that sildenafil improved erections in 69% of attempts versus 22% with placebo. Generic versions became available in December 2017 after Pfizer's patent exclusivity expired, and prices dropped rapidly. A 30-tablet supply of sildenafil 20 mg now costs $20 to $50 at most retail pharmacies without insurance, according to GoodRx pricing data and FDA Orange Book records.

Humana commercial formularies typically distinguish between the 20 mg tablet (which carries both the ED and pulmonary arterial hypertension indications) and the 25 mg, 50 mg, or 100 mg tablets (labeled exclusively for ED). The 20 mg strength often receives more favorable placement because it maps to a different National Drug Code and is sometimes classified under the cardiovascular therapeutic category. Members prescribed the 20 mg strength for ED may use three to five tablets to reach a 60 mg to 100 mg dose, which can affect quantity limit calculations.

Quantity limits on Humana commercial plans usually cap sildenafil at 6 to 12 tablets per 30 days for the ED indication. If your prescriber writes for the 20 mg strength at a higher tablet count (for example, 30 tablets of 20 mg per month), the pharmacy may trigger a clinical edit that requires a coverage review. Ask your prescriber to include the diagnosis code and intended dosing on the prescription to reduce fill delays.

How Humana Medicare Advantage Handles Sildenafil

Medicare Part D, which governs prescription drug coverage under Humana Medicare Advantage (MA) plans, specifically excludes medications used for erectile dysfunction or sexual dysfunction from required coverage. This is a CMS statutory exclusion under Section 1860D-2(e)(2)(A) of the Social Security Act, not a Humana-specific policy decision.

That exclusion is blunt. It applies to all ED drugs by pharmacologic class, regardless of whether a cheaper generic exists. As a result, most Humana MA-PD plans will deny a claim for sildenafil when the prescriber documents an ED diagnosis (ICD-10 code N52.x). The denial is not a formulary tier issue. It is a categorical benefit exclusion.

There is one exception worth understanding. Sildenafil 20 mg tablets carry a separate FDA-approved indication for pulmonary arterial hypertension (PAH), marketed under the brand name Revatio. When prescribed for PAH with the appropriate ICD-10 code (I27.0 or I27.2), Humana MA plans typically cover sildenafil 20 mg because the PAH indication falls outside the CMS ED exclusion. The Galiè et al. SUPER-1 trial (N=278) published in the New England Journal of Medicine demonstrated that sildenafil 20 mg three times daily improved six-minute walk distance by 45 meters versus placebo in PAH patients.

Members who have both ED and a documented cardiovascular or pulmonary condition should discuss with their physician whether the clinical picture supports a non-ED diagnosis code. This is not about gaming the system. Sildenafil was originally developed as a cardiovascular agent, and its vasodilatory effects are clinically relevant beyond penile hemodynamics.

Prior Authorization Requirements on Humana

For Humana commercial plans, generic sildenafil for ED rarely triggers a prior authorization (PA) requirement when dispensed within the plan's standard quantity limits. The drug sits on the preferred generic tier, and most point-of-sale edits are limited to quantity and days-supply checks.

PA requirements become relevant in three scenarios. First, if the prescribed quantity exceeds the plan's limit (for example, more than 12 tablets per month). Second, if the member is on a Humana plan with a closed formulary that requires PA for all PDE5 inhibitors. Third, and most commonly, if the member is enrolled in a Humana Medicare Advantage plan and the claim is submitted with an ED diagnosis.

On MA plans, the PA process for sildenafil is functionally a denial pathway. Because CMS excludes ED drugs from Part D coverage, submitting a PA for sildenafil with an N52.x code will result in a coverage determination letter denying the request. The turnaround time for a standard coverage determination is 72 hours for expedited requests and 7 days for standard requests under CMS Part D guidelines.

If your physician believes sildenafil is medically necessary for a non-ED indication (such as Raynaud phenomenon, PAH, or altitude sickness prophylaxis), they should submit the PA with the corresponding diagnosis code and a letter of medical necessity citing the relevant clinical evidence. The American College of Chest Physicians guidelines recommend sildenafil as a first-line oral therapy for WHO Group 1 PAH, which provides strong clinical justification for non-ED coverage.

Step Therapy: Is It Required?

Humana does not generally impose step therapy requirements for generic sildenafil on commercial plans. Sildenafil is itself the first-step agent in most PDE5 inhibitor step therapy protocols. If a plan requires step therapy for branded ED drugs like Cialis (tadalafil) or Stendra (avanafil), the step they require is usually a trial of generic sildenafil first.

The American Urological Association (AUA) guidelines on erectile dysfunction list PDE5 inhibitors as first-line pharmacotherapy, and sildenafil is the most widely studied drug in the class. There is no clinical or formulary logic for requiring a patient to fail another therapy before trying sildenafil. Any step therapy edit that blocks generic sildenafil on a commercial plan is likely a system error, and the pharmacy or prescriber should contact Humana's pharmacy benefit manager to resolve it.

On Medicare Advantage plans, step therapy is irrelevant for ED-indicated sildenafil because the drug is categorically excluded. No sequence of prior drug trials will overcome the CMS statutory exclusion.

How to Appeal a Humana Denial for Sildenafil

If Humana denies coverage for generic sildenafil, the appeal process depends on whether you are on a commercial plan or a Medicare Advantage plan. Both pathways start with an internal appeal.

For commercial plans, the process involves two levels. The first level is an internal appeal filed within 180 days of the denial. Include a letter of medical necessity from your prescriber, relevant medical records, and any clinical guidelines supporting the prescription. Humana must respond within 30 calendar days for a standard appeal or 72 hours for an expedited appeal. If the first-level appeal is denied, a second-level internal review is available, followed by an external review through an independent review organization (IRO).

For Medicare Advantage plans, the appeal pathway is more structured. After an initial coverage determination denial, you file a Level 1 redetermination with Humana within 60 days. If denied again, the case goes to a Level 2 reconsideration through MAXIMUS Federal Services, the CMS-contracted independent review entity. MAXIMUS reviews the case independently of Humana. If MAXIMUS upholds the denial, further appeals go to an Administrative Law Judge (Level 3), the Medicare Appeals Council (Level 4), and ultimately federal court (Level 5).

Practically speaking, ED-indication denials on Medicare Advantage plans are very difficult to overturn because the exclusion is statutory, not clinical. The most successful appeals involve reframing the clinical indication. Dr. Arthur Burnett, a professor of urology at Johns Hopkins, has noted: "Sildenafil's pharmacology extends well beyond erectile function. In patients with concurrent cardiovascular disease, its vasodilatory properties may address multiple clinical endpoints simultaneously."

For a straightforward commercial plan denial due to quantity limits, success rates on appeal are high. Include the prescriber's dosing rationale and a citation to the Goldstein et al. trial data showing dose-dependent efficacy at 25 mg, 50 mg, and 100 mg.

Cash-Pay and Manufacturer Savings Alternatives

If Humana denies coverage or if your copay exceeds the cash price, paying out of pocket for generic sildenafil is often the most practical option. Generic sildenafil costs $20 to $50 for a 30-tablet supply at most retail pharmacies. That price is sometimes lower than a Tier 1 copay on high-deductible Humana plans.

Manufacturer savings cards (sometimes called copay cards) are available for branded Viagra but not for generic sildenafil itself, since generics are produced by multiple manufacturers (Teva, Greenstone, Aurobindo, and others) without a single sponsor running a patient assistance program. However, pharmacy discount programs from GoodRx, RxSaver, and Amazon Pharmacy's RxPass frequently offer generic sildenafil at $3 to $10 per fill.

Humana members using a discount card instead of insurance should be aware that those fills will not count toward their plan's deductible or out-of-pocket maximum. For members close to meeting their deductible, running the claim through insurance (even at a higher copay) may be the better financial strategy for the calendar year.

Mail-order pharmacies in Humana's network, including CenterWell Pharmacy (Humana's own mail-order service), often provide 90-day supplies of generic sildenafil at a reduced per-tablet cost. CenterWell typically offers Tier 1 generics at $0 for a 90-day supply on many commercial plans.

Sildenafil Dosing and Formulary Considerations

Understanding how sildenafil is dosed helps explain some of the formulary quirks on Humana plans. The FDA-approved dosing for ED is 50 mg taken approximately one hour before sexual activity, with a range of 25 mg to 100 mg based on efficacy and tolerability. Most patients stabilize at 50 mg or 100 mg.

The 20 mg tablet, originally approved for PAH at a dose of 20 mg three times daily, is commonly prescribed off-label for ED at higher tablet counts (three to five tablets per dose). This approach can create confusion at the pharmacy because Humana's system may flag a claim for 30 tablets of sildenafil 20 mg as exceeding quantity limits, even though the total monthly dose is within normal clinical range.

Prescribers can avoid this problem by writing for the 50 mg or 100 mg tablet strength when the intent is ED treatment. These strengths are on Humana's formulary and carry quantity limits calibrated for on-demand ED dosing (typically 6 to 12 tablets per 30 days). The per-tablet cost for 100 mg is often identical to 20 mg at the generic level, so there is no cost penalty for using the higher-strength tablet.

A 2018 meta-analysis by Yuan et al. (N=5,096 across 25 RCTs) confirmed that sildenafil at 50 mg and 100 mg produced statistically significant improvements in erectile function versus placebo, with the 100 mg dose showing a slightly higher response rate (82% vs. 74%) but also a higher incidence of headache and flushing.

What If You Switch From a Commercial Plan to Medicare?

Members transitioning from a Humana commercial plan to Humana Medicare Advantage during retirement or disability qualification should plan for the loss of ED drug coverage. This transition catches many patients off guard because sildenafil may have been a $5 copay on their employer plan and is suddenly a full out-of-pocket expense.

The transition steps are straightforward. Before your commercial coverage ends, ask your prescriber for a 90-day prescription filled through your commercial plan's mail-order pharmacy. This gives you a supply bridge. After the switch to MA, set up a cash-pay arrangement through CenterWell or a retail pharmacy with a discount card. At $20 to $50 per month, generic sildenafil remains affordable for most patients even without insurance coverage.

If you are enrolled in a Humana Medicare Supplement (Medigap) plan rather than Medicare Advantage, note that Medigap plans do not include prescription drug coverage at all. You would need a standalone Part D plan for drug coverage, and that Part D plan would still be subject to the CMS ED drug exclusion.